- The trend backdrop is active with a 51-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is constructive, supporting the smart-money activity read.
LAVI
ATH
Week ended 07 Aug 2026
Weekly Investor Report
Lavipharm S.A. · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
1.55 EUR
-2.5%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 10.5% above the Trend Line and sits at 80.9% of its 52-week range. The latest completed week returned -2.5%, after a 4.8% four-week move. The latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal.
Setup score
58
out of 100
Latest Close
1.55 EUR
7 Aug 2026
1W Return
-2.5%
latest completed week
4W Return
4.8%
short-term follow-through
12W Return
-4.3%
quarterly tape
Trend Breadth
98.1%
51 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- Activity pressure is negative, which weakens the current setup.
- 1 reversal markers appear in the recent smart-money tape.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-2.5%
Latest completed week; four-week move 4.8%.
Indicator stack
99/11
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
3 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 10.5% above the Trend Line and sits at 80.9% of its 52-week range. The latest completed week returned -2.5%, after a 4.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7612-week average 0.90
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.76Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers
No recent accumulation markers. 1 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 4.8% over four weeks, -4.3% over 12 weeks, and 91.6% over one year. The current trend has remained active for 51 consecutive weeks.
Performance by holding period
Active trend streak51 weeks
Active weeks in one year51
Trend breadth98.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.89Latest activity-pressure read.
Pressure change-291.9%Four-week change in activity pressure.
Leadership13.56Latest relative-leadership reading.
RS change-15.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 3 relevant articles.
1 positive · 2 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-10.8%Distance below the 52-week high.
13-week volatility4.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2614 weeks finished lower.
Best week+16.8%Week of 10 Apr.
Worst week-11.8%Week of 6 Mar.
Latest week-2.5%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains3
Flat weeks1
Modest losses7
Sharp losses7
Recent vol4.3%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split29/21Count of positive and negative weeks in the 52-week window.
Average skew4.9% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGR Healthcare
4-week rank2 / 4
Group average3.4%
Trend breadth75.0%
Trend75.0%active weekly trend signals
MD50.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
IndustryGR Drug Manufacturers - Specialty & Generic
4-week rank1 / 2
Group average2.2%
Trend breadth100.0%
Trend100.0%active weekly trend signals
MD50.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape61/100
Trend, activity pressure, participation, and risk combine to a 61/100 tape read.
Indicator analysis76/100Latest 12-week confirmation: trend 12/12, activity pressure 7/12, relative leadership 12/12.
Activity pressure 0.76; 1 reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 3 relevant articles.
Lavipharm SA Actuals & Estimates (ATHEX:LAVI) Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1.55 EUR | -2.5% | 1.40 EUR | 0.91 EUR | -0.89 | 13.56 | 289.6K | On |
| 31 Jul 2026 | 1.59 EUR | 9.7% | 1.38 EUR | 0.90 EUR | -0.88 | 19.43 | 477.7K | On |
| 24 Jul 2026 | 1.45 EUR | 2.1% | 1.36 EUR | 0.90 EUR | -0.87 | 13.21 | 510.7K | On |
| 17 Jul 2026 | 1.42 EUR | -4.0% | 1.35 EUR | 0.89 EUR | -0.63 | 13.62 | 280.6K | On |
| 10 Jul 2026 | 1.48 EUR | -1.6% | 1.33 EUR | 0.89 EUR | -0.23 | 15.98 | 334.3K | On |
| 3 Jul 2026 | 1.50 EUR | -2.6% | 1.31 EUR | 0.88 EUR | 0.09 | 17.53 | 43.3K | On |
| 26 Jun 2026 | 1.54 EUR | -1.6% | 1.29 EUR | 0.88 EUR | 0.31 | 25.86 | 34.9K | On |
| 19 Jun 2026 | 1.57 EUR | 1.9% | 1.26 EUR | 0.87 EUR | 0.62 | 27.65 | 260.2K | On |
| 12 Jun 2026 | 1.54 EUR | -2.7% | 1.24 EUR | 0.87 EUR | 0.59 | 29.18 | 94.8K | On |
| 5 Jun 2026 | 1.58 EUR | -4.5% | 1.21 EUR | 0.86 EUR | 0.59 | 37.66 | 98.6K | On |
| 29 May 2026 | 1.65 EUR | 6.4% | 1.19 EUR | 0.85 EUR | 0.69 | 44.51 | 1.7M | On |
| 22 May 2026 | 1.55 EUR | -4.1% | 1.16 EUR | 0.85 EUR | 0.54 | 43.34 | 739.6K | On |
| 15 May 2026 | 1.62 EUR | -4.6% | 1.14 EUR | 0.84 EUR | 0.50 | 52.69 | 582.4K | On |
| 8 May 2026 | 1.70 EUR | 10.3% | 1.11 EUR | 0.83 EUR | 0.49 | 59.54 | 1.3M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.